Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMDW) Current Deferred Revenue (2018 - 2023)

Historic Current Deferred Revenue for Revolution Medicines (RVMDW) over the last 6 years, with Q1 2023 value amounting to $1.4 million.

  • Revolution Medicines' Current Deferred Revenue fell 8745.74% to $1.4 million in Q1 2023 from the same period last year, while for Mar 2023 it was $1.4 million, marking a year-over-year decrease of 8745.74%. This contributed to the annual value of $4.5 million for FY2022, which is 6391.81% down from last year.
  • Latest data reveals that Revolution Medicines reported Current Deferred Revenue of $1.4 million as of Q1 2023, which was down 8745.74% from $4.5 million recorded in Q4 2022.
  • Revolution Medicines' Current Deferred Revenue's 5-year high stood at $17.1 million during Q4 2019, with a 5-year trough of $1.4 million in Q1 2023.
  • For the 5-year period, Revolution Medicines' Current Deferred Revenue averaged around $11.0 million, with its median value being $11.8 million (2020).
  • As far as peak fluctuations go, Revolution Medicines' Current Deferred Revenue surged by 1618.09% in 2022, and later crashed by 8745.74% in 2023.
  • Revolution Medicines' Current Deferred Revenue (Quarter) stood at $17.1 million in 2019, then dropped by 29.27% to $12.1 million in 2020, then increased by 2.04% to $12.4 million in 2021, then tumbled by 63.92% to $4.5 million in 2022, then plummeted by 67.84% to $1.4 million in 2023.
  • Its Current Deferred Revenue stands at $1.4 million for Q1 2023, versus $4.5 million for Q4 2022 and $9.7 million for Q3 2022.